磷脂酰肌醇3-激酶信号通路及其抑制剂在淋巴瘤中的研究进展  

Progress of phosphatidylinositol 3-kinase signaling pathway and its inhibitors in lymphoma

作　　者：许雅虹 李纯团[1] 朱雄鹏[1] Xu Yahong;Li Chuntuan;Zhu Xiongpeng(Department of Hematology, the First Hospital of Quanzhou, Fujian Medical University, Quanzhou 362000, China)

机构地区：[1]福建医科大学附属泉州第一医院血液科,362000

出　　处：《白血病．淋巴瘤》2019年第9期568-571,共4页Journal of Leukemia & Lymphoma

基　　金：福建省自然科学基金(2017J01349).

摘　　要：磷脂酰肌醇3-激酶(PI3K)信号通路过度活化与恶性肿瘤的发生发展密切相关,该通路异常表达参与调控细胞的生长增殖、恶性转化、凋亡及转移,针对PI3K信号通路特定位点制定的靶向治疗是近年来的研究热点,多种不同类型的PI3K抑制剂已经上市或进入临床试验阶段,并对恶性淋巴瘤的治疗起着可观疗效,文章对PI3K信号通路在淋巴瘤中的活化形式及PI3K抑制剂在淋巴瘤中的最新研究进展作一综述。The over-activation of phosphatidylinositol 3-kinase (PI3K) signaling pathway is closely related to the occurrence and development of malignant tumors. The abnormal expression of this pathway is involved in the regulation of cell growth, malignant transformation, apoptosis and metastasis. The targeted therapy for specific sites of PI3K signaling pathway is a new research hotspot. A variety of different types of PI3K inhibitors have been marketed or entered clinical trials and have shown considerable efficacy in the treatment of malignant lymphomas. In this view, the recent advances in activation patterns of PI3K signaling pathway in lymphoma and PI3K inhibitors are summarized.

关 键 词：淋巴瘤 磷脂酰肌醇3-激酶 信号传导 蛋白激酶抑制剂 

分 类 号：R733.1[医药卫生—肿瘤]